

SPARC/Sec/SE/2025-26/38

November 13, 2025

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.

*Scrip Symbol:* SPARC

*Scrip Code:* 532872

Dear Sir/ Madam,

**Sub: SPARC announces consolidation of R&D laboratories and facilities**

Pursuant to the requirement under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that as part of the Company's strategic growth plan, the Company has decided to consolidate its R&D infrastructure and laboratories from multiple sites in Mumbai and Baroda to two sites in Baroda.

This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations, enhancing operational efficiencies and reducing cycle times.

The R&D operations being conducted at Mahakali site in Mumbai and Makarpura site in Baroda will be integrated into the Company's Savli and Tandalja sites in Baroda. As part of the overall cost optimization effort, the Company will outsource some of the R&D activities to third party partners on an as needed basis. The consolidation of laboratory operations and the increased outsourcing could result in excess capacity in certain functions, which the Company aims to streamline by the end of FY26.

The Company's corporate functions will continue to operate out of Mahakali office in Mumbai.

We would like to further inform that the transition is not expected to have any impact on the prioritization and scale of our current pipeline.

Kindly take the above on record.

**For Sun Pharma Advanced Research Company Ltd.**

**Kajal Damania**  
**Company Secretary and Compliance Officer**